By Kent Heckenlively, JD
Somebody has to be an optimist.
I really don’t have any problem with being the optimist. And I don’t have a problem with somebody else being the pessimist. (Or realist, if you prefer!) It’s why my wife and I make such a good team. I create the vision and she sweats the details. Twenty-two years of marriage and we’re still going strong.
So let me tell you what my optimist mind says: WE CAN END THE AUTISM EPIDEMIC BY JUNE OF 2020.
It is dependent upon YOU signing and sharing this petition so that by July 9, 2017 we have 100,000 signatures.
And when I speak of the end of the autism epidemic, what do I really mean? I mean that we recover the more than one million individuals with autism, many of them now young adults and living in special homes because they have become too much for their parents to care for at home.
I am speaking of a scientific framework for understanding how vaccines are creating an entire generation of damaged children. And in understanding HOW this is happening, we create the societal awareness to stop this nightmare.
Why am I so confident that if I can get YOU and 99,998 other people to sign this petition that ALL OF THIS WILL BE FIXED BY JUNE OF 2020?
Even though I consider myself an optimist, I like to think my background as an attorney and science teacher requires me to have some evidence for my optimism. I think that one of the most difficult issues in autism is that there is NO BIOLOGICAL TEST WHICH TELLS US THIS CHILD HAS AUTISM AND THIS ONE DOES NOT.
HOW CAN YOU TARGET A DISEASE FOR WHICH THERE IS NO TARGET?
That’s what I love about CELL DANGER THEORY as developed by Dr. Robert Naviaux of the University of California, San Diego. He HAS A TARGET, the abnormal pattern of metabolites which indicate the cells are not communicating properly with each other. He has published on this pattern in autism AND in chronic fatigue syndrome (ME/CFS), and believes it may be the key to at least 20 more chronic diseases.
Naviaux’s cell danger theory proposes that when cells encounter some chemical, virus, or pathogen that they can’t identify, (immature immune system or novel substance) they respond by shutting down communication with other cells, prompting a decrease in energy production by the mitochondria. Trouble ensues.
He has shown that he can normalize this cellular communication by treating it with a century old medication, suramin, originally developed to treat African Sleeping Sickness. Naviaux used LOW-DOSES of suramin to achieve this result.
The patients in the Naviaux study attained suramin blood levels of 5-15 um. Typical treatment levels for those being treated over the past 100 years for African Sleeping Sickness is 50-100 um in the blood for a period of 1-3 months. The high doses for cancer chemotherapy used by cancer researchers in the 1980s were blood levels of 150-270 um for a period of 3-6 months. AT THOSE LEVELS THERE IS TOXICITY.
Naviaux demonstrated his proof of concept for suramin in three different animal studies. It is called antipurinergic therapy.
The first group Naviaux used were mice who had autism induced through ‘maternal immune activation’, a commonly accepted proxy for autism. (Antipurinergic Therapy Corrects the Autism-Like Features in the Poly (IC) Mouse Model, PLoSOne, 2014)
The second group were mice who had autism induced in a similar manner, but were the human age equivalent of thirty years old. (Reversal of Autism-Like Behaviors and Metabolism with Single-Dose Antipurinergic Therapy, Translational Psychiatry, 2014)
The third group were genetically designed to have Fragile X syndrome, often called ‘genetic autism.’ (Antipurinergic Therapy Corrects the Autism-Like Features in the Fragile X (Fmr1 knockout) Mouse Model, Molecular Autism, 2015)
Naviuax has recently completed and published a small human trial showing the temporary normalization of cellular communication in children with autism, and at least for a time, resumption of normal development. (Low-Dose Suramin in Autism Spectrum Disorder: A Small Phase I/II, Randomized Clinical Trial, Annals of Clinical and Translational Neurology, 2017)
I always tell my students that the explanation of any scientific process should be simple, elegant, and even beautiful in its own way. I have spoken to Dr. Naviaux and know what he thinks is likely. He thinks that patients will need infusions (or some way to deliver the medicine) every six to eight weeks, allowing the cellular communication networks to build. Depending on the severity of the problem, treatment should probably be no more than one or two years, then it would be self-sustaining.
What was once so confusing and overwhelming comes into clear understanding.
I think the path is clear and it’s what I put in my White House petition.
One, have the White House meet with Dr. Naviaux and have him come up with a treatment protocol.
Two, have the FDA approve suramin for this ‘off-label’ use.
Three, have Congress fully fund and monitor. Up to this point, a good amount of the funding has been coming directly from Dr. Naviaux.
Personally, I think we can solve this problem in two years. My wife made me put three years. Here’s that petition again.
By Kent Heckenlively, JD
Read original article here